AC Immune SA (ACIU) plans to raise $55 million in an initial public offering on Friday, September 23rd. The company will be issuing 4,600,000 shares at $11.00-$13.00 per share.

In the last 12 months, AC Immune SA generated $45.1 million in revenue and $21.4 million in net income. AC Immune SA has a market cap of $647.3 million.

Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

AC Immune SA provided the following description of their company for its IPO: “We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer’s disease, or AD, and Parkinson’s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. “.

AC Immune SA was founded in 2003 and has 62 employees. The company is located at EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland and can be reached via phone at +41 21 693 91 21 or on the web at http://www.acimmune.com.

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with Analyst Ratings Network's FREE daily email newsletter.